This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Bristol-Myers (BMY) to Post Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Bristol-Myers (BMY) Q1 earnings might have gained from strong demand for Eliquis and incremental contribution from newer drugs. Operating expenses might have jumped on broader portfolio-related costs.
Alexandria (ARE) Q1 FFO Beats Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Alexandria Real Estate's (ARE) reports better-than-anticipated first-quarter 2022 performance attributable to healthy leasing activity and solid internal growth.
Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $77.56, marking a +0.36% move from the previous day.
Prothena (PRTA) Stock Gains 51% in a Year: What Lies Ahead?
by Zacks Equity Research
Prothena (PRTA) has had a phenomenal run in the past year, primarily due to its promising pipeline for AD.
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $77.28 in the latest trading session, marking a +1.15% move from the prior day.
Biotech Stock Roundup: NKTR Plunges on Deal Termination, REGN Offers Update & More
by Zacks Equity Research
Regulatory and pipeline updates from Nektar (NKTR) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
Exelixis (EXEL) Outperforms Industry YTD: What Lies Ahead?
by Zacks Equity Research
Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.
Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FLQL
Exelixis (EXEL) Initiates Early Stage Study of Lymphoma
by Zacks Equity Research
Exelixis (EXEL) commences the dose-escalation stage of the phase I study of XL114 in patients with non-Hodgkin's lymphoma.
Nektar (NKTR) Ends Bempeg Plus Opdivo Program on Study Failures
by Zacks Equity Research
Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development programs.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $77.51 in the latest trading session, marking a +0.83% move from the prior day.
Bristol Myers' (BMY) Opdivo Data Positive for Neoadjuvant NSCLC
by Zacks Equity Research
Bristol Myers (BMY) posts favorable data from a late-stage study that shows neoadjuvant Opdivo with chemotherapy to significantly better the event-free survival rate in patients with resectable NSCLC.
Bristol Myers Squibb (BMY) Stock Moves -1.63%: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $76.50, moving -1.63% from the previous trading session.
Iovance (IOVA) Stock Rallies 33% in a Month: Here's Why
by Zacks Equity Research
Iovance (IOVA) to complete the FDA filing for its lead candidate in melanoma by August. It will start a clinical study for its first TALEN-edited TIL therapy for two advanced cancer indications later this year.
The Zacks Analyst Blog Highlights Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals
by Zacks Equity Research
Bristol Myers, Vir Biotechnology, Gilead Sciences, and Vertex Pharmaceuticals are part of top Analyst article.
Zacks Investment Ideas feature highlights: Regeneron and Bristol-Myers Squibb
by Zacks Equity Research
Regeneron and Bristol-Myers Squibb are part of today's Investment Idea article.
BioPharma Giants Print Fresh All-Time Highs
by Bryan Hayes
The trend is our friend in this market, and these two biopharmaceutical stocks are trending exceptionally well.
Biotech Stock Roundup: VIR Down on Regulatory News, BMY Offers Updates & More
by Zacks Equity Research
Regulatory and pipeline news from Vir Biotechnology (VIR) and Bristol Myers (BMY) are a few key highlights from the biotech sector during the past week.
Iovance (IOVA) to Seek FDA Nod for Melanoma Therapy in August
by Zacks Equity Research
Iovance (IOVA) expects to complete FDA filing for lifileucel in metastatic melanoma by August 2022. It also intends to start a phase III combo study with lifileucel in melanoma in late 2022.
Bristol Myers (BMY) Gets EC Nod for CAR T Cell Therapy Breyanzi
by Zacks Equity Research
The European Commission grants marketing authorization to Bristol Myers' (BMY) Breyanzi for treating certain forms of relapsed or refractory large b-cell lymphoma.
Implied Volatility Surging for Bristol-Myers (BMY) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Bristol-Myers (BMY) stock based on the movements in the options market lately.
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $74.43 in the latest trading session, marking a +0.87% move from the prior day.